• Also Known As:
  • B2M
  • β2-Microglobulin
  • Thymotaxin
  • Formal Name:
  • Beta2 Microglobulin
  • Serum or Urine
Board approved icon
Medically Reviewed by Expert Board.

This page was fact checked by our expert Medical Review Board for accuracy and objectivity. Read more about our editorial policy and review process.

This article was last modified on

At a Glance

Why Get Tested?

To help detect kidney damage and follow kidney disorders; sometimes to monitor people who are exposed to cadmium

When To Get Tested?

When you have symptoms and signs associated with kidney dysfunction; periodically if you work with cadmium

Sample Required?

A blood sample drawn from a vein in your arm; sometimes a random or 24-hour urine sample

Test Preparation Needed?


You may be able to find your test results on your laboratory’s website or patient portal. However, you are currently at Testing.com. You may have been directed here by your lab’s website in order to provide you with background information about the test(s) you had performed. You will need to return to your lab’s website or portal, or contact your healthcare practitioner in order to obtain your test results.

Testing.com is an award-winning patient education website offering information on laboratory tests. The content on the site, which has been reviewed by laboratory scientists and other medical professionals, provides general explanations of what results might mean for each test listed on the site, such as what a high or low value might suggest to your healthcare practitioner about your health or medical condition.

The reference ranges for your tests can be found on your laboratory report. They are typically found to the right of your results.

If you do not have your lab report, consult your healthcare provider or the laboratory that performed the test(s) to obtain the reference range.

Laboratory test results are not meaningful by themselves. Their meaning comes from comparison to reference ranges. Reference ranges are the values expected for a healthy person. They are sometimes called “normal” values. By comparing your test results with reference values, you and your healthcare provider can see if any of your test results fall outside the range of expected values. Values that are outside expected ranges can provide clues to help identify possible conditions or diseases.

While accuracy of laboratory testing has significantly evolved over the past few decades, some lab-to-lab variability can occur due to differences in testing equipment, chemical reagents, and techniques. This is a reason why so few reference ranges are provided on this site. It is important to know that you must use the range supplied by the laboratory that performed your test to evaluate whether your results are “within normal limits.”

For more information, please read the article Reference Ranges and What They Mean.

What is being tested?

Beta-2 microglobulin (B2M) is a protein that is found on the surface of nucleated cells (contain a nucleus) and functions as part of the human immune system. This protein is routinely shed by cells into the blood and is present in most body fluids, with highest levels in the blood, generally lower levels in spinal fluid, and trace levels in urine.

In the kidneys, B2M passes through blood-filtering units called the glomeruli and is then reabsorbed by the renal proximal tubules, structures that reclaim water, proteins, vitamins, minerals, and other vital substances. Normally, only small amounts of B2M are present in the urine, but when the renal tubules become damaged or diseased, B2M concentrations increase due to the decreased ability to reabsorb this protein. When the glomeruli in the kidneys are damaged, they are unable to filter out B2M, so the level in the blood rises.

Common Questions

How is the test used?

The beta-2 microglobulin (B2M) test may be used when known physical or suspected kidney damage occurs to distinguish between glomerular and tubular disorders of the kidney. B2M levels will also increase with disorders that involve overactive cell turnover and when the immune system is activated, thus is not diagnostic for a specific disease. With renal failure, it provides additional information about someone’s likely prognosis and the health of their kidneys. B2M is measured in the following situations:

  • In kidney disease, both blood and urine B2M tests may be ordered along with other kidney function tests such as BUN, creatinine, and urine albumin (microalbumin) to evaluate kidney damage or disease and to distinguish between disorders that affect the glomeruli and the renal tubules.
  • Used to monitor persons with end-stage renal disease (ESRD)
  • Excess B2M can accumulate in joint spaces in long-term dialysis patients; this is called dialysis-related amyloidosis (DRA). A B2M test may be used to help evaluate a person for DRA.
  • B2M tests may sometimes be ordered to monitor people who have had a kidney transplant to detect early signs of rejection.
  • It may also be ordered to monitor people who are exposed to high levels of cadmium and/or other heavy metals like mercury, such as may occur with occupational exposure.

When is it ordered?

Both blood and urine B2M tests may be ordered when a person has signs and symptoms associated with kidney dysfunction and a healthcare practitioner wants to distinguish between disorders that affect the glomeruli and the renal tubules. Some signs and symptoms may include:

  • Swelling or puffiness (edema), particularly around the eyes or in the face, wrists or ankles
  • Urine that is foamy, bloody, pink or brownish
  • Protein in the urine
  • Fatigue, weakness
  • Nausea

A urine test may also be ordered periodically to monitor a person who has had a kidney transplant or to monitor those exposed to high concentrations of cadmium or mercury to detect early kidney dysfunction.

People who have been on dialysis for five years or more may develop dialysis-related amyloidosis (DRA), a condition resulting from the accumulation of excess B2M in the blood and eventually in the bone, joint, tendon (osteoarticular structure) and other body tissues such as heart, lung, and digestive tract. It is primarily diagnosed by tissue or bone biopsy. B2M levels are performed as part of the work-up in addition to imaging studies.

What does the test result mean?

Levels of B2M in the blood vary from low levels to four times the lower limit, and this is considered normal. B2M may be undetectable in the urine.

Increased levels of B2M in the blood and urine indicate that there is a problem but are not diagnostic of a specific disease or condition.

In someone with signs of kidney disease, increased levels of B2M in the blood and low levels in the urine indicate that the disorder is associated with glomeruli dysfunction. If B2M is low in the blood and high in the urine, then it is likely that the person has renal tubule damage or disease. Also, B2M levels correlate with risk of cardiovascular disease (CVD) and with cause of death in patients with kidney disease or on dialysis.

In a person who has been on long-term dialysis, an increase in B2M is associated with dialysis-related amyloidosis.

Increases in urine B2M in a person with a kidney transplant may indicate early kidney rejection.

Increases in someone who is exposed to high levels of cadmium or mercury may indicate early kidney dysfunction.

Can the test be done in my doctor's office?

No, the test requires specialized equipment and training and is not available in every laboratory. Your blood or urine may be sent to a reference laboratory.

How long will it take for results?

That depends on the laboratory performing the test. Since your sample may be sent to a reference laboratory for testing, it may take several days for results to be available.

Can I choose either a blood or a urine B2M test?

In most cases, the sample tested will be dictated by the reason that the test is being performed. It may be necessary to do a blood test, a urine test, or both together. In certain neurologic situations, cerebrospinal fluid (CSF) may also be tested. The results are not generally interchangeable.

If I have an elevated B2M, does it mean that I have been exposed to cadmium or mercury?

Generally, no. It means that you may have some early kidney damage that affects your renal tubules. If you work with or suspect that you have been exposed to cadmium or mercury, then your doctor will order specific tests for cadmium or mercury in your blood and/or urine (see the article on Heavy Metals).

Is there anything else I should know?

Conditions associated with an increased rate of cell production or destruction, severe infections, viral infections such as CMV (cytomegalovirus), and some conditions that activate the immune system, such as inflammatory conditions and autoimmune disorders, can cause increases in beta-2 microglobulin levels, but the test is not typically ordered to monitor these conditions.

Drugs such as lithium, cyclosporine, cisplatin, carboplatin, gentamicin, interferon-α, and aminoglycoside antibiotics can increase B2M blood and/or urine concentrations.

Increases in blood and urine B2M can be seen with certain cancers, including multiple myeloma, leukemia, and lymphoma. When there is central nervous system involvement, increased B2M may also be found in the cerebrospinal fluid. B2M may also be present in infectious and cerebrovascular disorders. In cases of HIV, an inverse correlation between B2M and CD4+ T-lymphocytes has been shown to mark disease progression.

B2M is increased in patients with peripheral artery disease (PAD).

Recent nuclear medicine procedures and radiographic contrast media can affect test results.

In people with kidney disease who are undergoing dialysis, B2M can form long protein chains that can be deposited in joints and tissues, causing stiffness and pain. This condition is called B2M dialysis-associated amyloidosis.

View Sources

Sources Used in Current Review

2017 review performed by Rita Khoury, MD, DABCC, FACB, Laboratory Director, Aculabs, Inc.

Surovi Hazarika, Brian H. Annex. (2017) Biomarkers and Genetics in Peripheral Artery Disease. Clinical Chemistry Jan 2017, 63 (1) 236-244.

Giuseppe Coppolino, Davide Bolignano, Laura Rivoli,  et al. (2014) Tumour Markers and Kidney Function: A Systematic Review. BioMed Research International Volume 2014 (2014), Article ID 647541, 9 pages.

Sedighi O, Abediankenari S, Omranifar B. (2015) Association Between Plasma Beta-2 Microglobulin Level and Cardiac Performance in Patients With Chronic Kidney Disease. Nephro-urology Monthly. 2015;7(1):e23563. doi:10.5812/numonthly.23563.

Zeng X, Hossain D, Bostwick DG, Herrera GA, Ballester B, et al. (2014) Urinary β2-Microglobulin is a Sensitive Indicator for Renal Tubular Injury. SAJ Case Rep 1: 103. doi: 10.18875/2375-7043.1.103.

Anita Basu, MD, FACP; Vecihi Batuman, MD, FASNl Reynaldo Matute, MD, et al. (2017) Dialysis-Related Beta-2m Amyloidosis. Available online at http://emedicine.medscape.com/article/246542-overview. Accessed May 2017.

Sources Used in Previous Reviews

Pagana, K. D. & Pagana, T. J. (© 2007). Mosby’s Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 155-156.

Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 742-743.

Basu, A. et. al. (Updated 2008 February 22). Amyloidosis, Beta2M (Dialysis-Related) eMedicine [On-line information]. Available online at http://emedicine.medscape.com/article/246542-overview. Accessed August 2009.

Holmes, R. et. al. (Updated: 2009 July 30). Amyloidosis, Overview. eMedicine [On-line information]. Available online at http://emedicine.medscape.com/article/335414-overview. Accessed August 2009.

(Updated 2008 September). Renal Function Markers – Kidney Disease. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/RenalDz/RenalFunctionMarkers.html?client_ID=LTD. Accessed August 2009.

(© 1995–2009). Overview: Beta-2 Microglobulin (B[2]-M), Urine. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/300243. Accessed August 2009.

(© 1995–2009). Overview: Beta-2-Microglobulin (Beta-2-M), Serum. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/9234. Accessed August 2009.

(2006 May). Amyloidosis and Kidney Disease. National Kidney and Urologic Diseases Information Clearinghouse [On-line information]. Available online at http://kidney.niddk.nih.gov/kudiseases/pubs/amyloidosis/. Accessed August 2009.

Basu, A. et. al. (Updated 2012 August 2). Dialysis-Related Beta-2m Amyloidosis. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/246542-overview. Accessed June 2013.

Gooptu, M. and Scarpaci, A. (Updated 2012 April 6). Beta2-Microglobulin. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/2086864-overview. Accessed June 2013.

Beta-2-Microglobulin (Beta-2-M), Serum. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/9234. Accessed June 2013.

Liabeuf, S. (2012 August 15). Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney International (2012) 82, 1297–1303 Abstract [On-line information]. Available online at http://www.nature.com/ki/journal/v82/n12/abs/ki2012301a.html. Accessed June 2013.

(Updated 2010 September 9). Amyloidosis and Kidney Disease. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [On-line information]. Available online at http://kidney.niddk.nih.gov/kudiseases/pubs/amyloidosis/. Accessed June 2013.

Winchester, J. (2005 July). Novel Changes in Beta2-Microglobulin in Dialysis Patients. Clinical Chemistry v 51 (7) 1089-1090 [On-line information]. Available online at http://www.clinchem.org/content/51/7/1089.full. Accessed June 2013.

Pagana, K. D. & Pagana, T. J. (© 2011). Mosby’s Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 680-682.

Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER, Bruns DE, eds. 4th edition, St. Louis: Elsevier Saunders; 2006, pg 555.

Rao LV, Pechet L, Jenkins A, et al. Laboratory tests, in Wallach’s Interpretation of Diagnostic Tests, 9th ed. (2011) Williamson MA, Snyder ML, eds. Lippincott Williams & Wilkins. Chapter 2.

Ask a Laboratory Scientist

Ask a Laboratory Scientist

This form enables patients to ask specific questions about lab tests. Your questions will be answered by a laboratory scientist as part of a voluntary service provided by one of our partners, American Society for Clinical Laboratory Science. Please allow 2-3 business days for an email response from one of the volunteers on the Consumer Information Response Team.

Send Us Your Question